IRIS
MARRONE, Aldo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.755
NA - Nord America 5.532
AS - Asia 4.573
SA - Sud America 847
AF - Africa 51
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 2
Totale 18.766
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.435
RU - Federazione Russa 3.329
SG - Singapore 1.745
IE - Irlanda 1.364
CN - Cina 1.148
BR - Brasile 718
HK - Hong Kong 714
UA - Ucraina 692
IT - Italia 597
GB - Regno Unito 583
DE - Germania 435
SE - Svezia 239
VN - Vietnam 221
KR - Corea 200
FI - Finlandia 193
TR - Turchia 192
GR - Grecia 127
JP - Giappone 125
IN - India 111
FR - Francia 73
AR - Argentina 54
CA - Canada 49
AT - Austria 27
MX - Messico 27
BE - Belgio 25
BD - Bangladesh 24
ID - Indonesia 21
EC - Ecuador 18
NL - Olanda 16
IQ - Iraq 14
VE - Venezuela 13
CZ - Repubblica Ceca 12
ZA - Sudafrica 12
CO - Colombia 11
PL - Polonia 11
MA - Marocco 10
PE - Perù 10
CL - Cile 9
IR - Iran 9
EG - Egitto 8
PY - Paraguay 7
UZ - Uzbekistan 7
EU - Europa 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
ES - Italia 5
HN - Honduras 5
PK - Pakistan 5
RO - Romania 5
UY - Uruguay 5
DZ - Algeria 4
JM - Giamaica 4
KE - Kenya 4
BG - Bulgaria 3
CH - Svizzera 3
ET - Etiopia 3
HR - Croazia 3
HU - Ungheria 3
JO - Giordania 3
LT - Lituania 3
NP - Nepal 3
PA - Panama 3
PS - Palestinian Territory 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
AL - Albania 2
AM - Armenia 2
GE - Georgia 2
PH - Filippine 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TW - Taiwan 2
UG - Uganda 2
AU - Australia 1
BB - Barbados 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GT - Guatemala 1
IL - Israele 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LI - Liechtenstein 1
LK - Sri Lanka 1
MK - Macedonia 1
MY - Malesia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
OM - Oman 1
PR - Porto Rico 1
QA - Qatar 1
SR - Suriname 1
SV - El Salvador 1
TJ - Tagikistan 1
Totale 18.766
Salva come PNG Salva come JPEG
Città #
Dublin 1.358
Moscow 1.071
Jacksonville 1.046
Santa Clara 718
Chandler 714
Hong Kong 714
Singapore 690
New York 263
Princeton 210
Seoul 200
Roxbury 158
Woodbridge 139
Ashburn 136
Hefei 130
Beijing 127
Ann Arbor 126
The Dalles 124
Boardman 121
Cambridge 116
Bremen 110
Wilmington 104
Medford 100
Dallas 93
Ho Chi Minh City 85
Bengaluru 76
Munich 76
Caserta 64
Jinan 60
São Paulo 57
Naples 56
San Mateo 53
Shenyang 52
Nanjing 50
Des Moines 43
Mountain View 41
Hanoi 40
Düsseldorf 33
Los Angeles 31
Zhengzhou 31
Guangzhou 26
Brussels 25
Nanchang 25
Hangzhou 22
Napoli 22
Rio de Janeiro 22
Houston 21
Changsha 20
Helsinki 19
Norwalk 19
Washington 19
Haikou 18
Nuremberg 18
Tianjin 18
Brasília 17
Shanghai 16
Hebei 15
Ningbo 15
Belo Horizonte 14
Lanzhou 14
Taiyuan 14
Auburn Hills 13
Ottawa 13
Seattle 13
Frankfurt am Main 12
Haiphong 12
Taizhou 12
Kunming 11
London 11
Rome 11
Turku 11
Vienna 11
Amsterdam 10
Campinas 10
Jiaxing 10
Milan 10
Tokyo 10
Atlanta 9
Curitiba 9
Padova 9
Sorocaba 9
Thái Nguyên 9
Toronto 9
Warsaw 9
Da Nang 8
Dearborn 8
Istanbul 8
Marano Di Napoli 8
Porto Alegre 8
Salvador 8
Shenzhen 8
Caracas 7
Chennai 7
Chicago 7
Falkenstein 7
Guarulhos 7
Guayaquil 7
Marigliano 7
Montreal 7
Changchun 6
Contagem 6
Totale 10.182
Salva come PNG Salva come JPEG
Nome #
Cannabinoid receptor 2-63 QQ varianti s associated with severe necroinflammation in chronic epatiti C 167
Abdominal fat interacts with PNPLA3 I148M, but not with the APOC3 variant in the pathogenesis of liver steatosis in chronic hepatitis C 154
Mechanisms and clinical behavior of hepatocellular carcinoma in HBV and HCV infection and alcoholic and non-alcoholic fatty liver disease 150
Anti-envelope 1 and 2 immune response in chronic hepatitis C patients: Effects of hepatitis B virus co-infection and interferon treatment 143
Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C. 143
Cannabinoid receptor 2-63 QQ variant is associated with persistently normal aminotransferase serum levels in chronic hepatitis C 135
Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms 134
Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration 133
Activity of aminoglycosides against phagocytosed bacteria 130
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment. 127
Cannabinoid Receptor 2 (CB2) Q63 variant in chronic hepatitis C: an association with a more severe hepatocellular necrosis. 125
Absence of hepatitis C viral infection among patients with primary Sjogren's syndrome 123
Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic—Standardized National Screening or One Tailored to Local Epidemiology? 122
Non-invasive respiratory support in SARS-CoV-2 related acute respiratory distress syndrome: when is it most appropriate to start treatment? 121
Chronic HCV infection and neurological and psychiatric disorders: an overview. 121
Cannabinoid receptor 2 (CB2) Q63 variant is associated with a severe histological activity index in patients with chronic hepatitis C 118
Analisi della regione del core promoter del virus dell’epatite B (HBV) in pazienti guariti da una malattia oncoematologica con infezione cronica da HBV o da HBV-HCV tre anni dopo sieroconversione ad anti-HBe. 118
CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection. 117
Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. 115
COVID-19 and arrhythmia: The factors associated and the role of myocardial electrical impulse propagation. An observational study based on cardiac telemetric monitoring 114
Analisi della regione del core promoter del virus dell’epatite B (HBV) in pazienti guariti da una malattia oncoematologica con infezione cronica da HBV o da HBV-HCV tre anni dopo sieroconversione ad anti-HBe 112
IMPACT OF TYPE II DIABETES ON HCC APPEARANCE IN PATIENTS TREATED WITH DIRECT ACTING ANTIVIRALS 109
Predictors of in-hospital mortality of COVID-19 patients and the role of telemetry in an internal medicine ward during the third phase of the pandemic 109
Advances in the Diagnosis and Monitoring of Hepatitis C Virus Infection 108
Tenofovir disoproxil fumarate monotherapy maintains HBV suppression achieved by a "de novo" combination of lamivudine-adefovir: a pilot study 108
Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: a multicenter prospective study 108
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 107
HBV Infection and Host Interactions: The Role in Viral Persistence and Oncogenesis 106
Chronic hepatitis B infection in pediatric patients cured of oncologic diseases: natural history and effect of interferon treatment 106
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort 104
Effect of prednisone priming followed by alpha-interferon in treatment of children with chronic hepatitis B: an interim analysis of a controlled trial 104
The impact of the CB2-63 polymorphism on the histological presentation of chronic hepatitis B. 104
PNPLA3 l148M variant as a risk factor for carotid atherosclerosis in chronic epatiti C 103
Prolonged treatment of children with chronic hepatitis B with recombinant alpha 2a-interferon: a controlled, randomized study 101
Atherosclerosis and chronic hepatitis C virus (HCV) infection: Role of liver steatosis 101
Eighteen-month lamivudine prophylaxis on preventing occult hepatitis B virus infection reactivation in patients with haematological malignancies receiving immunosuppression therapy 100
Immunocompromised patients with HBsAg a determinant mutants: comparison of HBsAg diagnostic assays 99
Three-phase sequential combined treatment with lamivudine and interferon in young patients with chronic hepatitis B 99
A hyper-glycosilation of HBV surface major hydrophilic region characterizes HBV reactivation driven by immunosuppression and affects HBsAg recognition in vitro 99
Clinical application of lung ultrasound score on COVID-19 setting: a regional experience in Southern Italy 99
Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of COVID-19 patients requiring supplemental O2 therapy: a prospective controlled non-randomized study 99
Prediction of SARS-CoV-2-Related Lung Inflammation Spreading by V:ERITAS (Vanvitelli Early Recognition of Inflamed Thoracic Areas Spreading) 99
Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study 98
Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. 98
Hepatic steatosis and necro-inflammatory activity overestimated liver stiffness by transient elastography in staging liver fibrosis in chronic hepatitis C 98
A hyper-glycosilation of HBV surface major hydrophilic correlates with immunosuppression-driven HBV reactivation and hampers HBsAg recognition in vitro 98
Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection 97
HCV-related steatosis and risk of atherosclerosis 97
Esperienza con l'interferone linfoblastoide nelle epatiti croniche virali 97
Favourable effect of alpha-interferon treatment in HBeAb/HBV-DNA positive chronic hepatitis B. 97
Authors’ response 97
La epatite cronica da HCV con steatosi si associa ad elevato rischio aterosclerotico. 96
Ruolo patogenetico dell'adiponectina nella steatosi associata ad epatite C 96
Viral Hepatitis C 96
Efficacy and safety of the sofosbuvir/velpatasvir combination for the treatment of patients with early mild to moderate COVID-19 96
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 95
Treatment of chronic hepatitis B in children with prednisone followed by alpha-interferon: a controlled randomized study 95
Leukocyte interferon-alpha and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon 95
Aspetti diagnostici di mutanti della regione HBsAg in pazienti immunocompromessi con riattivazione dell’infezione da virus dell’epatite B (HBV). 95
Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatitis C patients 94
Baseline HBV-DNA level is an important predictor of response to interferon in children with chronic hepatitis B 94
Espressione dell'infezione da citomegalovirus (CMV) in pazienti cardiotrapiantati 94
Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B 94
A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection 94
Mortality and risk factors of vaccinated and unvaccinated COVID-19 frail patients treated with anti-SARS-CoV-2 monoclonal antibodies. A real-world study 93
Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. 93
A Case Report on Treatment of Nonhealing Leg Ulcer: Do Not Forget the Underlying Disease 93
Interplay between oxidative stress and hepatic steatosis in the progression of chronic hepatitis C 92
Core promoter mutations 3 years after anti-hepatitis B e seroconversion in patients with chronic hepatitis B or hepatitis B and C infection and cancer remission 92
Treatment of chronic hepatitis B: efficacy of current drugs and prospects for the future 92
EFFICACIA DEL TRATTAMENTO CON INTERFERONE RICOMBINANTE E LINFOBLASTOIDE IN PAZIENTI CON EPATITE CRONICA DA HCV 92
Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations. 92
Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct‐acting antivirals 92
Interferon-induced anti-HBE seroconversion correlates with a Th1 cytokine shift following emergence of core promoter mutations in chronic hepatitis B 91
Ricerca del sangue occulto nelle feci con Hemoquant: prevenzione e diagnostica. 91
Le complicanze infettive in pazienti sottoposti a trapianto di cuore: dati del centro napoletano. 91
Le infezioni respiratorie da Branhamella catarrhalis in pazienti sottoposti a trapianto di cuore. 91
Predictors of early and late hepatocellular carcinoma recurrence 89
Pleurite da Listeria monocytogenes in un paziente con cirrosi epatica: osservazione di un caso clinico 89
The TM6SFZ 8167K variant is an independent predictor of severe liver steatosis in chronic hepatitis C 89
Impact of chronic liver disease on SARS-CoV-2 infection outcomes: Roles of stage, etiology and vaccination 88
Gender Differences in the Pathogenesis and Risk Factors of Hepatocellular Carcinoma 88
Effects of long-term alfa interferon treatment in 344 patients with chronic hepatitis C: retrospective analysis of dosage and type of interferon used 88
Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis 88
Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta 88
Different serological, molecular and cytokine profiles characterize active and inactive disease in patients with chronic hepatitis B virus (HBV) infection 88
Favourable effect of alpha-interferon treatment in HBeAb/HBV-DNA positive chronic hepatitis B 88
Ruolo patogenetico dell’adiponectina nella steatosi associata ad epatite C 88
Hepatitis C virus infection in Italy: a multicentric sero-epidemiological study. (A report from the HCV study group of the Italian Association for the study of the liver) 87
Low HBeAg serum levels correlate with the presence of the double A1762T/G1764A core promoter mutation and a positive response to interferon in patients with chronic hepatitis B virus infection 87
Long term effect of interferon (IFN) treatment of chronic hepatitis B (CHB) in pediatric patients cured of oncologic diseases 87
Complicanze infettive in pazienti sottoposti a trapianto di cuore. 87
Treatment of chronic hepatitis B in children with prednisone followed by alfa-interferon: a controlled randomized study 86
Tm6sf2 e167k variant is associated with severe steatosis in chronic hepatitis c, regardless of pnapl3 polymorphism 86
Correlation of serum HBeAg levels and double A1762T/G1764A HBV core promoter mutation with response to interferon in patients with chronic hepatitis B 86
Changes in clinical scenarios, management, and perspectives of patients with chronic hepatitis C after viral clearance by direct-acting antivirals 86
Hepatitis B virus DNA quantitation and detection of core promoter, precore and polymerase mutations in chronic hepatitis B: evaluation and clinical usefulness of three new commercial assays 85
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine 84
Le infezioni delle basse vie urinarie: eziologia e suscettibilità agli antibiotici. Nostra esperienza negli ultimi 4 anni. 84
ESPERIENZA CON L'INTERFERONE LINFOBLASTOIDE NELLE EPATITI CRONICHE VIRALI 84
Totale 10.200
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.406
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.406
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021844 0 0 0 0 0 16 205 159 8 214 175 67
2021/20221.284 59 3 8 15 435 14 11 35 64 124 102 414
2022/20232.682 235 45 38 216 326 221 4 174 1.276 27 64 56
2023/20241.207 95 33 61 97 372 262 17 34 4 14 77 141
2024/20253.161 27 42 33 87 502 357 391 274 436 487 277 248
2025/20266.423 488 593 682 675 1.093 2.892 0 0 0 0 0 0
Totale 19.166